TargetMol

DOX?NOP1 HCl

Product Code:
 
TAR-T27200
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27200-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27200-500mg500mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
DOX-NOP1 is a molecular hybrid covalently joining doxorubicin (DOX) and NOP1. DOX-NOP1 showed similar increased toxicity toward resistant cancer cells and, in addition, lower cardiotoxicity than DOX.
CAS:
T27200
Molecular Weight:
973.31
Purity:
0.98
SMILES:
O=C(C1=C(C2=C(C(O)=C1C3=O)C[C@@](O)(C(COC(C4=CC=C(C(NCCCNC5=CC(C(F)(F)F)=C([N+]([O-])=O)C=C5)=O)C=C4)=O)=O)C[C@@H]2O[C@@H]6O[C@H]([C@H]([C@H](C6)N)O)C)O)C7=C3C=CC=C7OC.[H]Cl

References

Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance Konstantin ChegaevAurore FraixElena GazzanoGamal Eldein F. Abd-EllatefMarco BlangettiBarbara RolandoSabrina ConociChiara RigantiRoberta FrutteroAlberto GascoSalvatore Sortino Publication Date (Web): January 30, 2017 (Letter) doi: 10.1021/acsmedchemlett.7b00016